^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
GENE:

SEC23IP (SEC23 Interacting Protein)

i
Other names: SEC23IP, SEC23 Interacting Protein, P125, Intracellular Phospholipase A1 Beta, SEC23-Interacting Protein, IPLA1beta, MSTP053, IPLA1β, P125A
Associations
Trials
2ms
P125 International incidence trends for melanoma in children, teenagers and young adults: a systematic review. (PubMed, Br J Dermatol)
International trends varied with no unifying trend; however, there was evidence to suggest reducing trends in countries where incidence rates were higher (Australia and the USA). A greater understanding of trends by ethnicity, sun safety behaviour and the impact of public health campaigns is needed to better understand the trends, and a greater representation of developing countries is needed to understand the global burden.
Review • Journal
|
SEC23IP (SEC23 Interacting Protein)
4ms
And-1 coordinates with polymerase δ to regulate nucleotide excision repair and UVB-induced skin tumorigenesis. (PubMed, Nat Commun)
These mice exhibited impaired NER and developed keratoacanthomas upon chronic UVB exposure. Collectively, our findings uncover And-1 as a pivotal factor in NER-mediated DNA repair and highlight its role in skin tumorigenesis.
Journal
|
SEC23IP (SEC23 Interacting Protein)
1year
p12 isoform-2 is a regulatory subunit of human DNA polymerase delta and is dysregulated in various cancers. (PubMed, FEBS Lett)
Further, we observed dysregulated p12* expression in low-grade glioma, renal, thyroid, and pancreatic carcinomas. This study identifies a previously unrecognized Polδ complex and highlights a possible regulatory role of p12 variants in cellular phenotypes.
Journal
|
SEC23IP (SEC23 Interacting Protein)
over1year
Targeting POLD1 to suppress the proliferation and migration of breast cancer MDA-MB-231 cell lines by downregulation of SIRT1. (PubMed, Toxicol Res (Camb))
We aimed to investigate the downstream signaling pathway of EX-527, a potent and selective SIRT1 inhibitor, in MDA-MB-231 breast cancer cell lines, and the crosstalk between SIRT1 and POLD1, which is essential for the activities of polymerase δ...SIRT1 could have an oncogenic role in breast cancer development and progression via activating POLD1. These conclusions present new insights into the underlying mechanisms of TNBC.
Preclinical • Journal
|
TP53 (Tumor protein P53) • POLD1 (DNA Polymerase Delta 1) • SIRT1 (Sirtuin 1) • ANXA5 (Annexin A5) • SEC23IP (SEC23 Interacting Protein)
|
selisistat (SEN-196)
2years
Antibody-drug conjugate αEGFR-E-P125A reduces triple-negative breast cancer vasculogenic mimicry, motility, and metastasis through inhibition of EGFR, integrin, and FAK/STAT3 signaling. (PubMed, Cancer Res Commun)
In vivo, αEGFR-E-P125A treatment decreased primary tumor growth and VM, reduced lung metastasis, and confirmed the inhibition of signaling events observed in vitro. Simultaneous inhibition of EGFR and α5β1 integrin signaling by αEGFR-E-P125A is a promising strategy for the inhibition of VM, tumor growth, motility, and metastasis in TNBC and other EGFR-overexpressing tumors.
Journal
|
EGFR (Epidermal growth factor receptor) • IL6 (Interleukin 6) • SEC23IP (SEC23 Interacting Protein)
|
EGFR overexpression
almost3years
Capivasertib (C) + palbociclib (P) and fulvestrant (F) in patients (pts) with HR+/HER2_ advanced breast cancer (ABC): Phase 1b data from CAPItello-292 (ESMO-BC 2023)
Conclusions C+P+F was tolerable in heavily pre-treated pts with HR+/HER2− ABC, with no marked safety differences among dose levels. DLTs were consistent with the expected safety profile.
Clinical • P1 data • Metastases
|
HER-2 (Human epidermal growth factor receptor 2) • SEC23IP (SEC23 Interacting Protein)
|
HER-2 negative
|
Ibrance (palbociclib) • fulvestrant • Truqap (capivasertib)
almost3years
Mechanism of anti-EGFR antibody endostatin fusion protein action on inhibition of vasculogenic mimicry and tumor cell motility in triple negative breast cancer (AACR 2023)
Although expression of and signaling by the epidermal growth factor receptor (EGFR) is commonly seen in TNBC, anti-EGFR antibodies such as Cetuximab have had limited therapeutic efficacy, used alone or in combination with chemotherapy.Primary TNBC tumor growth and metastases require supporting vasculature, which develops through a combination of endothelial angiogenesis and vasculogenic mimicry (VM)...These results indicate that αEGFR-E-P125A suppressed both EGFR and α5β1 integrin signaling. Simultaneous inhibition of EGFR and α5β1integrin signaling by αEGFR-E-P125A fusion is a promising approach to inhibition of TNBC growth and metastases.
Tumor cell
|
STAT3 (Signal Transducer And Activator Of Transcription 3) • SEC23IP (SEC23 Interacting Protein)
|
Erbitux (cetuximab)
over3years
Adenosine diphosphate-ribosylation factor-like 15 can regulate glycolysis and lipogenesis related genes in colon cancer. (PubMed, J Physiol Pharmacol)
In summary, ARL15 may promote the occurrence of colon cancer by increasing the expression of protein kinase B/AMP-activated protein kinase (AKT/AMPK) downstream regulatory enzymes for glycogenesis and lipogenesis. JIB-04 can target ARL15 and affect its expression as well as the expressions of glucose and lipid metabolity-related proteins in AKT and AMPK signaling pathways.
Journal
|
FASN (Fatty acid synthase) • PKM (Pyruvate Kinase M1/2) • SEC23IP (SEC23 Interacting Protein)
over3years
RNA-sequencing of myxoinflammatory fibroblastic sarcomas reveals a novel SND1::BRAF fusion and 3 different molecular aberrations with the potential to upregulate the TEAD1 gene including SEC23IP::VGLL3 and TEAD1::MRTFB gene fusions. (PubMed, Virchows Arch)
The detected molecular aberrations have a potential to either activate the expression of genes regulated by the transcription factors of the TEAD family, which are involved in tumor initiation and progression, or switch on the MEK/ERK signaling cascade, which plays an important role in cell cycle progression. Our results broaden the molecular genetic spectrum of MIFS and point toward the importance of the VGLL3-TEAD interaction, as well as the deregulation of the MEK/ERK pathway in the pathogenesis of MIFS, and may represent a potential target for therapy of recurrent or advanced disease.
Journal
|
BRAF (B-raf proto-oncogene) • SEC23IP (SEC23 Interacting Protein)
|
BRAF fusion
over3years
Scrutinizing Deleterious Nonsynonymous SNPs and Their Effect on Human POLD1 Gene. (PubMed, Genet Res (Camb))
Among these deleterious nsSNPs, 23 showed a conservation scale of >5, 2 were predicted to be associated with binding site formation, and one acted as a posttranslational modification site. All of them were involved in coil, extracellular structures, or helix formation, and some cause the change in size, charge, and hydrophobicity.
Journal
|
POLD1 (DNA Polymerase Delta 1) • SEC23IP (SEC23 Interacting Protein)
|
POLD1 mutation